GL
GLEN.NS
—
—
Integrated Oil & Gas
Glenmark Pharmaceuticals Ltd
LatestGlenmark Pharmaceuticals flagged for bullish technical setup above ₹2,150
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,17 %
Op margin
10,2 %
ROE
13,0 %
Net margin
8,0 %
Debt / equity
0,06
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
Glenmark Pharmaceuticals Ltd is classified under Energy / Integrated Oil & Gas and appears profitable on the latest normalized snapshot.
Business. Glenmark Pharmaceuticals Ltd (GLEN.NS) is classified within the Integrated Oil & Gas industry, operating primarily through a product-sale revenue model. The company is listed under the ticker GLEN.NS, though specific exchange details are not provided in the available data. Information regarding its operating segments, headquarters location, and geographic presence is not available in the provided facts. Consequently, the company is described at the industry level as an integrated oil and gas entity.
Classification81 %
SectorEnergy
Business sectorOil & Gas
IndustryIntegrated Oil & Gas
Generated · rules-based
Sell-side consensus
BUY9 analysts
7 buy1 hold1 sell
Avg 12m price target2 236,27
Analyst recommendations
9 analysts · consensus BuyBuy7
Hold1
Sell1
12-month price target
2 236,27
Consensus of sell-side coverage.
At a glance
Score→
47
composite score
Valuation
—
valuation pending
Analysts→
Buy
9 analysts · indicative
Ownership
—
not yet wired
Profitability→
13,0 %
return on equity
Quality→
57
quality score (0-100)
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
1Sector rotation
Sector1D1Mvs mkt
Materials+2,2 %+1,6 %+2,4 %
Energy · THIS SECTOR+1,2 %+5,3 %+1,4 %
Real Estate+0,7 %+4,1 %+0,8 %
Health Care+0,7 %−0,5 %+0,8 %
Consumer Discretionary+0,3 %+8,7 %+0,5 %
Information Technology−0,3 %+6,6 %−0,1 %
Financials−0,3 %−4,5 %−0,1 %
Consumer Staples−1,0 %+3,0 %−0,8 %
Utilities−1,5 %−21,2 %−1,3 %
Industrials−1,7 %−2,3 %−1,6 %
Communication Services———
Developing storylines
No tracked sagas currently linked to GLEN.NS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-07-07
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Peers
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated · BP (BP)
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · 2026-07-07
Composite-score breakdown
Score breakdown47
Profitability+35
Sentiment+15
Risk penalty−3
Missing signals−3
Synthesis
Business
Glenmark Pharmaceuticals Ltd (GLEN.NS) is classified within the Integrated Oil & Gas industry, operating primarily through a product-sale revenue model. The company is listed under the ticker GLEN.NS, though specific exchange details are not provided in the available data. Information regarding its operating segments, headquarters location, and geographic presence is not available in the provided facts. Consequently, the company is described at the industry level as an integrated oil and gas entity.
Classification81 %
SectorEnergy
Business sectorOil & Gas
IndustryIntegrated Oil & Gas
AI synthesis
GENERATEDGlenmark Pharmaceuticals Ltd (GLEN.NS) is currently classified as Integrated Oil & Gas within Integrated Oil & Gas (Energy). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 199,078,760,000 INR, total equity 105,121,090,000, short-term debt 0, long-term debt 5,935,270,000. Net cash position is approximately -5,935,270,000 INR. Profitability profile: revenue 169,825,110,000, gross profit 122,350,480,000, operating income 17,328,520,000, net income 13,618,510,000. Return on equity ~13.0%. Return on assets ~6.8%. Operating-cash-flow to net-income ratio is 2.53. Risk profile from automated assessment: liquidity risk medium, dilution risk low. Flags: Net cash is negative after subtracting total debt.. Comparable peers identified within the same class: Chevron, Shell, BP.
Key takeaways
- Return on equity is about 13.0%.
- Debt to equity is about 0.06x.
- Likely peers from the same classification include Chevron, Shell, BP.
- Analyst estimate: Mean price target = 2,388.38 INR
Bull / Bear case
Generated · model-assistedBULL CASE · 4
Revenue grew 27.5% year-over-year to INR 169.8 billion in FY2026, demonstrating strong top-line expansion momentum.
Net income surged 30.1% to INR 13.6 billion in FY2026, indicating robust profitability recovery and growth.
Operating margin of 10.2% exceeds the cohort median of 8.92%, highlighting superior operational efficiency relative to peers.
Debt-to-equity ratio of 0.06 is significantly lower than the cohort median of 0.29, reflecting a conservative capital structure.
BEAR CASE · 3
The company faces a medium level of liquidity risk, which could constrain financial flexibility during market stress periods.
Capex to revenue ratio of -7.99% is below the cohort median, potentially indicating underinvestment in future growth drivers.
Long-term debt increased to INR 5.9 billion in FY2026 from INR 2.5 billion in FY2025, showing rising leverage obligations.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-05-29
Q1 2026 · Quarter highlights
Revenue INR 37.71B, +15,8% YoY; Operating income +283,0% YoY.
RevenueINR 37.71B+15,8 % YoY
Operating incomeINR 2.41B+283,0 % YoY
Net incomeINR 3.01B+6 382,0 % YoY
Free cash flow—
EPS—
Operating cash flowINR 34.45B+516,3 % YoY
Financials
Income statement
RevenueINR 37.71B
Gross profitINR 25.98B
Operating incomeINR 2.41B
Net incomeINR 3.01B
Margins
Gross margin68.9%
Operating margin6.4%
Net margin8.0%
FCF margin—
Balance sheet
Total assetsINR 199.08B
Total liabilitiesINR 93.96B
Total equityINR 105.12B
Cash & equivalents—
Long-term debtINR 5.94B
Cash flow
Operating cash flowINR 34.45B
CapEx-INR 13.58B
Free cash flow—
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 37.71B, +15,8% YoY
- ▍Operating income +283,0% YoY
- ▍Net income +6 382,0% YoY
- ▍Net margin 8.0%
QUARTERLYFiled 2026-01-30
Q4 2025 · Quarter highlights
Revenue INR 39.01B, +15,2% YoY; Operating income +11,2% YoY.
RevenueINR 39.01B+15,2 % YoY
Operating incomeINR 5.31B+11,2 % YoY
Net incomeINR 4.03B+15,9 % YoY
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
RevenueINR 39.01B
Gross profitINR 26.06B
Operating incomeINR 5.31B
Net incomeINR 4.03B
Margins
Gross margin66.8%
Operating margin13.6%
Net margin10.3%
FCF margin—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 39.01B, +15,2% YoY
- ▍Operating income +11,2% YoY
- ▍Net income +15,9% YoY
- ▍Net margin 10.3%
QUARTERLYFiled 2025-11-14
Q3 2025 · Quarter highlights
Revenue INR 60.47B, +76,1% YoY; Operating income +73,0% YoY.
RevenueINR 60.47B+76,1 % YoY
Operating incomeINR 8.33B+73,0 % YoY
Net incomeINR 6.10B+72,3 % YoY
Free cash flow—
EPS—
Operating cash flowINR 28.36B+461,8 % YoY
Financials
Income statement
RevenueINR 60.47B
Gross profitINR 47.82B
Operating incomeINR 8.33B
Net incomeINR 6.10B
Margins
Gross margin79.1%
Operating margin13.8%
Net margin10.1%
FCF margin—
Balance sheet
Total assetsINR 190.02B
Total liabilitiesINR 94.20B
Total equityINR 95.82B
Cash & equivalents—
Long-term debtINR 12.24B
Cash flow
Operating cash flowINR 28.36B
CapEx-INR 5.00B
Free cash flow—
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 60.47B, +76,1% YoY
- ▍Operating income +73,0% YoY
- ▍Net income +72,3% YoY
- ▍Net margin 10.1%
QUARTERLYFiled 2025-08-14
Q2 2025 · Quarter highlights
Revenue INR 32.64B, +0,6% YoY; Operating income −72,9% YoY.
RevenueINR 32.64B+0,6 % YoY
Operating incomeINR 1.27B−72,9 % YoY
Net incomeINR 468.7M−86,2 % YoY
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
RevenueINR 32.64B
Gross profitINR 22.49B
Operating incomeINR 1.27B
Net incomeINR 468.7M
Margins
Gross margin68.9%
Operating margin3.9%
Net margin1.4%
FCF margin—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 32.64B, +0,6% YoY
- ▍Operating income −72,9% YoY
- ▍Net income −86,2% YoY
- ▍Net margin 1.4%
QUARTERLYFiled 2025-05-23
Q1 2025 · Quarter highlights
Revenue INR 32.56B; Operating income INR 630.0M.
RevenueINR 32.56B
Operating incomeINR 630.0M
Net incomeINR 46.5M
Free cash flow—
EPS—
Operating cash flow-INR 8.28B
Financials
Income statement
RevenueINR 32.56B
Gross profitINR 21.67B
Operating incomeINR 630.0M
Net incomeINR 46.5M
Margins
Gross margin66.6%
Operating margin1.9%
Net margin0.1%
FCF margin—
Balance sheet
Total assetsINR 160.50B
Total liabilitiesINR 72.00B
Total equityINR 88.49B
Cash & equivalents—
Long-term debtINR 24.73B
Cash flow
Operating cash flow-INR 8.28B
CapEx-INR 7.51B
Free cash flow—
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 32.56B
- ▍Operating income INR 630.0M
- ▍Net margin 0.1%
QUARTERLYFiled 2025-02-14
Q4 2024 · Quarter highlights
Revenue INR 33.88B; Operating income INR 4.77B.
RevenueINR 33.88B
Operating incomeINR 4.77B
Net incomeINR 3.48B
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
RevenueINR 33.88B
Gross profitINR 23.03B
Operating incomeINR 4.77B
Net incomeINR 3.48B
Margins
Gross margin68.0%
Operating margin14.1%
Net margin10.3%
FCF margin—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 33.88B
- ▍Operating income INR 4.77B
- ▍Net margin 10.3%
QUARTERLYFiled 2024-11-14
Q3 2024 · Quarter highlights
Revenue INR 34.34B; Operating income INR 4.82B.
RevenueINR 34.34B
Operating incomeINR 4.82B
Net incomeINR 3.54B
Free cash flow—
EPS—
Operating cash flow-INR 7.84B
Financials
Income statement
RevenueINR 34.34B
Gross profitINR 23.64B
Operating incomeINR 4.82B
Net incomeINR 3.54B
Margins
Gross margin68.8%
Operating margin14.0%
Net margin10.3%
FCF margin—
Balance sheet
Total assetsINR 152.35B
Total liabilitiesINR 67.90B
Total equityINR 84.46B
Cash & equivalents—
Long-term debtINR 17.81B
Cash flow
Operating cash flow-INR 7.84B
CapEx-INR 2.46B
Free cash flow—
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 34.34B
- ▍Operating income INR 4.82B
- ▍Net margin 10.3%
QUARTERLYFiled 2024-08-14
Q2 2024 · Quarter highlights
Revenue INR 32.44B; Operating income INR 4.70B.
RevenueINR 32.44B
Operating incomeINR 4.70B
Net incomeINR 3.40B
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
RevenueINR 32.44B
Gross profitINR 21.34B
Operating incomeINR 4.70B
Net incomeINR 3.40B
Margins
Gross margin65.8%
Operating margin14.5%
Net margin10.5%
FCF margin—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 32.44B
- ▍Operating income INR 4.70B
- ▍Net margin 10.5%
ANNUALFiled 2026-05-29
FY 2026 · Full-year highlights
Revenue INR 169.83B, +27,5% YoY; Operating income +16,1% YoY.
RevenueINR 169.83B+27,5 % YoY
Operating incomeINR 17.33B+16,1 % YoY
Net incomeINR 13.62B+30,1 % YoY
Free cash flowINR 4.37B−38,7 % YoY
EPS—
Operating cash flowINR 34.45B+516,3 % YoY
Financials
Income statement
RevenueINR 169.83B
Gross profitINR 122.35B
Operating incomeINR 17.33B
Net incomeINR 13.62B
Margins
Gross margin72.0%
Operating margin10.2%
Net margin8.0%
FCF margin2.6%
Balance sheet
Total assetsINR 199.08B
Total liabilitiesINR 93.96B
Total equityINR 105.12B
Cash & equivalents—
Long-term debtINR 5.94B
Cash flow
Operating cash flowINR 34.45B
CapEx-INR 13.58B
Free cash flowINR 4.37B
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 169.83B, +27,5% YoY
- ▍Operating income +16,1% YoY
- ▍Net income +30,1% YoY
- ▍Free cash flow −38,7% YoY
- ▍Net margin 8.0%
ANNUALFiled 2025-05-23
FY 2025 · Full-year highlights
Revenue INR 133.22B, +12,8% YoY; Operating income +619,1% YoY.
RevenueINR 133.22B+12,8 % YoY
Operating incomeINR 14.93B+619,1 % YoY
Net incomeINR 10.47B+169,7 % YoY
Free cash flowINR 7.12B+131,9 % YoY
EPS—
Operating cash flow-INR 8.28B−81,0 % YoY
Financials
Income statement
RevenueINR 133.22B
Gross profitINR 84.33B
Operating incomeINR 14.93B
Net incomeINR 10.47B
Margins
Gross margin63.3%
Operating margin11.2%
Net margin7.9%
FCF margin5.3%
Balance sheet
Total assetsINR 160.50B
Total liabilitiesINR 72.00B
Total equityINR 88.49B
Cash & equivalents—
Long-term debtINR 24.73B
Cash flow
Operating cash flow-INR 8.28B
CapEx-INR 7.51B
Free cash flowINR 7.12B
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 133.22B, +12,8% YoY
- ▍Operating income +619,1% YoY
- ▍Net income +169,7% YoY
- ▍Free cash flow +131,9% YoY
- ▍Net margin 7.9%
ANNUALFiled 2024-05-24
FY 2024 · Full-year highlights
Revenue INR 118.13B, +2,0% YoY; Operating income −195,8% YoY.
RevenueINR 118.13B+2,0 % YoY
Operating income-INR 2.88B−195,8 % YoY
Net income-INR 15.02B−605,2 % YoY
Free cash flow-INR 22.33B−902,7 % YoY
EPS—
Operating cash flow-INR 4.57B−173,0 % YoY
Financials
Income statement
RevenueINR 118.13B
Gross profitINR 68.10B
Operating income-INR 2.88B
Net income-INR 15.02B
Margins
Gross margin57.6%
Operating margin-2.4%
Net margin-12.7%
FCF margin-18.9%
Balance sheet
Total assetsINR 143.59B
Total liabilitiesINR 65.11B
Total equityINR 78.48B
Cash & equivalents—
Long-term debtINR 12.31B
Cash flow
Operating cash flow-INR 4.57B
CapEx-INR 9.15B
Free cash flow-INR 22.33B
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 118.13B, +2,0% YoY
- ▍Operating income −195,8% YoY
- ▍Net income −605,2% YoY
- ▍Free cash flow −902,7% YoY
- ▍Net margin -12.7%
ANNUALFiled 2023-05-19
FY 2023 · Full-year highlights
Revenue INR 115.83B, −5,9% YoY; Operating income −81,0% YoY.
RevenueINR 115.83B−5,9 % YoY
Operating incomeINR 3.00B−81,0 % YoY
Net incomeINR 2.97B−68,4 % YoY
Free cash flow-INR 2.23B−129,0 % YoY
EPS—
Operating cash flowINR 6.26B−43,5 % YoY
Financials
Income statement
RevenueINR 115.83B
Gross profitINR 68.85B
Operating incomeINR 3.00B
Net incomeINR 2.97B
Margins
Gross margin59.4%
Operating margin2.6%
Net margin2.6%
FCF margin-1.9%
Balance sheet
Total assetsINR 193.72B
Total liabilitiesINR 98.98B
Total equityINR 94.74B
Cash & equivalents—
Long-term debtINR 46.08B
Cash flow
Operating cash flowINR 6.26B
CapEx-INR 6.08B
Free cash flow-INR 2.23B
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue INR 115.83B, −5,9% YoY
- ▍Operating income −81,0% YoY
- ▍Net income −68,4% YoY
- ▍Free cash flow −129,0% YoY
- ▍Net margin 2.6%
Valuation TTM
Market price
$2 384,90
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$105.12B
Net cashⓘ
-$5.94B
Current ratioⓘ
1.8
Debt / equityⓘ
0.1
ROAⓘ
6.8%
ROEⓘ
13.0%
Cash conversionⓘ
253.0%
CapEx / revenueⓘ
-8.0%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Active Pharmaceutical Ingredients (API)—
low · llm_fanout_v2
Over-the-Counter (OTC) Healthcare—
low · llm_fanout_v2
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 46 %
EPS
Consensus EPS
83,73
Predicted surprise
+0,01
Beat probability
46 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio 0,02 · as of 2026-07-06 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 83,73 |
| Revenue | —no estimate | —no estimate | 166,1B INR |
| Operating income | —no estimate | —no estimate | 29,8B INR |
Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-07-07
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy4
Buy3
Hold2
Sell0
Strong sell0
12-month price target$2 388,38 · Median $2 575,00
Low $1 500,41High $2 750,00
Operating income · consensus29,8B INR
EPS surprise
+53,5 %
reported vs consensus · beat
Revenue surprise
+2,2 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$1 500,41
Mean$2 236,27
Median$2 350,00
High$2 735,00
Spot$2 384,90
−6.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin10,2 %Above median
Net Margin8,0 %Above median
ROE13,0 %Above P75
Capex / Rev-8,0 %Below median
D/E0,06Above median
Cash Conv2,53Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Return On Assetsnet_income / total_assets
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- Glenmark Pharmaceuticals Ltd Market data — financials · 2026-07-06
- Glenmark Pharmaceuticals Ltd Market data — analyst estimates · 2026-07-06
- Glenmark Pharmaceuticals Ltd Market data — ESG · 2026-07-06
- Glencore PLC — company reference export (2026-07-05) · 2026-07-06
Ownership & reference
Insider activity
— missing data
Short positioning
— missing data
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
GLEN.NSCanonical
— · USD
Intel & risk
peak dispatch · 2026-07-07
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companyPeerSector
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 20:34 UTCEARNINGSQuarterly results — Q1 2026 Revenue INR 37.71B · Net INR 3.01B
2026-05-29 20:34 UTCEARNINGSAnnual results — FY 2026 Revenue INR 169.83B · Net INR 13.62B
2026-01-30 20:08 UTCEARNINGSQuarterly results — Q4 2025 Revenue INR 39.01B · Net INR 4.03B
2025-11-14 17:54 UTCEARNINGSQuarterly results — Q3 2025 Revenue INR 60.47B · Net INR 6.10B
2025-08-14 18:01 UTCEARNINGSQuarterly results — Q2 2025 Revenue INR 32.64B · Net INR 468.7M
2025-05-23 20:01 UTCEARNINGSQuarterly results — Q1 2025 Revenue INR 32.56B · Net INR 46.5M
2025-05-23 20:01 UTCEARNINGSAnnual results — FY 2025 Revenue INR 133.22B · Net INR 10.47B
2025-02-14 18:25 UTCEARNINGSQuarterly results — Q4 2024 Revenue INR 33.88B · Net INR 3.48B
2024-11-14 19:17 UTCEARNINGSQuarterly results — Q3 2024 Revenue INR 34.34B · Net INR 3.54B
2024-08-14 17:58 UTCEARNINGSQuarterly results — Q2 2024 Revenue INR 32.44B · Net INR 3.40B
2024-05-24 20:31 UTCEARNINGSAnnual results — FY 2024 Revenue INR 118.13B · Net INR -15.02B
2023-05-19 19:05 UTCEARNINGSAnnual results — FY 2023 Revenue INR 115.83B · Net INR 2.97B
2022-05-29 18:27 UTCEARNINGSAnnual results — FY 2022 Revenue INR 123.05B · Net INR 9.42B
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage